Athenex Overview
Latest ROE for Athenex: 1589.72% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow1589.72%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Athenex (ATNX) currently reports a ROE of 1589.72%. That is above the Healthcare sector average of 22.76%. Use the charts on this page to explore Athenex's ROE history and peer comparisons.
Athenex's ROE of 1589.72% is higher than the Healthcare sector average of 22.76%. That is roughly 6883.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Athenex's current 1589.72% should be judged against Healthcare norms (sector average: 22.76%) and against ATNX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 1589.72%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Athenex, and consider following ATNX for alerts when major investors trade the stock.
Athenex is classified in the Healthcare sector. On ROE, it currently shows 1589.72% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATNX with unrelated industries.
